ImmuneRegen BioSciences has announces a Materials Transfer Agreement (MTA) with HemoGenix®, a Contract Research Service Laboratory that provides a 21st-century approach to developing stem cell assays for the biotechnology and pharmaceutical industry.
ImmuneRegen says that its high-throughput technology imparts standardization of stem cell assays, making HemoGenix a valuable collaborator. As part of the agreement, ImmuneRegen will ship its therapeutic candidate Homspera® for testing using a number of proprietary tools developed and validated by HemoGenix.
HemoGenix will explore the potential of Homspera to stimulate hematopoietic stem cell proliferation and differentiation using their instrument-based ATP bioluminescence technology.
By combining a traditional approach for examining stem cell differentiation with a fluorescent tool for measuring proliferation, HemoGenix provides a way to standardize and validate the widely-used stem cell colony-forming cell differentiation assay.
Earlier studies performed by ImmuneRegen have shown the ability of Homspera to modify the number of leukocytes circulating in the blood of animals exposed to lethal and sub lethal doses of ionizing radiation.
Additional studies are underway to better understand this activity and explore potential therapeutic capabilities in fields as diverse as cancer, immunological disorders, wound healing, regenerative medicine and radioprotection.
The agreement with HemoGenix highlights ImmuneRegen’s continued progress in its research and development efforts. ImmuneRegen has recently announced research initiatives with a number of major partners in the biotechnology industry, and has sourced $3 million of capital to continue Homspera product development.